Accelerating thrombolysis of arterial thrombus with NO-MBs UTMD therapy

• DOI: 10.1016/j.ejpb.2024.114566
• Publication Date: 2024-10-30T06:59:39Z
• Authors: Binbin Shi; Qiaohua Yang; Zenghui Liang; Runjie Yu; Hui Li; Qilong Wu; Mingling Fang; Lili Lin; Huafang Chen; Yingzheng Zhao; Bin Chen

Arterial thrombotic disease is a common and serious clinical medical problem. Nitric oxide (NO), as therapeutic gas, can delay the progression of thrombosis reduce tissue ischemia hypoxia damage. However, systemic delivery NO causes complications, in body easily cleared by hemoglobin blood. In this study, we designed lipid microbubble carrying (NO-MBs) combined with ultrasound-targeted destruction (UTMD) technology to achieve targeted under real-time contrast-enhanced ultrasound monitoring. The good stability NO-MBs was demonstrated examining changes diameter, concentration intensity time. Moreover, vivo vitro thrombolysis experiments, it confirmed that combination UTMD could accelerate arterial thrombolysis. Meanwhile, levels inflammatory factors, superoxide dismutase (SOD) malondialdehyde (MDA) vascular after treatment were detected, which showed significantly response oxidative stress induced thromboembolism. addition, so to‌ evaluate safety strategy, MTT assay, hemolysis test, detection serum biochemical indicators, H&E staining major organs performed. results strategy had excellent biosafety. conclusion, has great potential diseases.